Perrigo Company plc Accrued Liabilities, Current
Perrigo Company plc (PRGO) had Accrued Liabilities, Current of $363.10 million as of 2025-09-27, per its 10-Q filed 2025-11-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2025-11-05
- 2025-09-27: Accrued Liabilities, Current $363.10M.
- 2025-06-28: Accrued Liabilities, Current $327.90M.
- 2025-03-29: Accrued Liabilities, Current $253.80M.
- 2024-12-31: Accrued Liabilities, Current $238.70M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2025-09-27 | $363.10M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $327.90M 10-Q · filed 2025-08-06 | |
| 2025-03-29 | $253.80M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $238.70M 10-Q · filed 2025-11-05 | |
| 2024-09-28 | $227.00M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | $218.50M 10-Q · filed 2024-08-02 | |
| 2024-03-30 | $359.00M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $335.40M 10-Q · filed 2024-11-06 | |
| 2023-09-30 | $262.30M 10-Q · filed 2023-11-07 | |
| 2023-07-01 | $261.70M 10-Q · filed 2023-08-08 | |
| 2023-04-01 | $272.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $250.20M 10-K · filed 2024-02-27 | |
| 2022-10-01 | $242.70M 10-Q · filed 2022-11-08 | |
| 2022-07-02 | $240.70M 10-Q · filed 2022-08-09 | |
| 2022-04-02 | $270.80M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $279.40M 10-K · filed 2023-02-28 | |
| 2021-10-02 | $339.90M 10-Q · filed 2021-11-12 | |
| 2021-07-03 | $235.50M 10-Q · filed 2021-08-11 | |
| 2021-04-03 | $267.90M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $183.10M 10-K · filed 2022-03-01 | $250.30M 10-K · filed 2021-03-01 |
| 2020-09-26 | $237.00M 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $240.60M 10-Q · filed 2020-08-05 | |
| 2020-03-28 | $248.60M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $229.20M 10-K · filed 2021-03-01 | |
| 2019-09-28 | $213.10M 10-Q · filed 2019-11-06 | |
| 2019-06-29 | $262.70M 10-Q · filed 2019-08-08 | |
| 2019-03-30 | $232.00M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $201.30M 10-K · filed 2020-02-27 | |
| 2018-09-29 | $194.10M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $192.80M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $205.30M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $230.80M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $274.60M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $240.80M 10-Q · filed 2017-08-10 | |
| 2017-04-01 | $281.60M 10-Q · filed 2017-05-30 | |
| 2016-12-31 | $263.30M 10-K · filed 2018-03-01 | |
| 2016-10-01 | $258.70M 10-Q/A · filed 2017-05-23 | |
| 2016-07-02 | $295.70M 10-Q/A · filed 2017-05-22 | |
| 2016-04-02 | $343.20M 10-Q/A · filed 2017-05-22 | $307.50M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $351.90M 10-K · filed 2018-03-01 | $308.40M 10-KT · filed 2016-02-25 |
| 2015-09-26 | $308.80M 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $257.50M 10-K · filed 2017-05-22 | $246.40M 10-K · filed 2015-08-13 |
| 2015-03-28 | $230.20M 10-Q · filed 2015-04-29 | |
| 2014-12-27 | $230.10M 10-Q · filed 2015-02-05 | |
| 2014-09-27 | $179.90M 8-K · filed 2014-11-20 | |
| 2014-06-28 | $174.10M 10-K · filed 2017-05-22 | $179.40M 10-K · filed 2014-08-14 |
| 2014-03-29 | $152.50M 10-Q · filed 2014-05-07 | |
| 2013-12-28 | $140.60M 10-Q · filed 2014-02-06 | |
| 2013-06-29 | $95.70M 10-K · filed 2014-08-14 | $95.60M 10-Q · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |